ELEV vs. SBBP, RAIN, INKT, BOLT, AVEO, MESO, SRRK, TSHA, EXAI, and CRGX
Should you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Strongbridge Biopharma (SBBP), Rain Oncology (RAIN), MiNK Therapeutics (INKT), Bolt Biotherapeutics (BOLT), AVEO Pharmaceuticals (AVEO), Mesoblast (MESO), Scholar Rock (SRRK), Taysha Gene Therapies (TSHA), Exscientia (EXAI), and CARGO Therapeutics (CRGX). These companies are all part of the "medical" sector.
Strongbridge Biopharma (NASDAQ:SBBP) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
52.0% of Strongbridge Biopharma shares are owned by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are owned by institutional investors. 5.1% of Strongbridge Biopharma shares are owned by insiders. Comparatively, 8.1% of Elevation Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Strongbridge Biopharma received 285 more outperform votes than Elevation Oncology when rated by MarketBeat users. However, 70.27% of users gave Elevation Oncology an outperform vote while only 51.15% of users gave Strongbridge Biopharma an outperform vote.
Strongbridge Biopharma has higher revenue and earnings than Elevation Oncology. Elevation Oncology is trading at a lower price-to-earnings ratio than Strongbridge Biopharma, indicating that it is currently the more affordable of the two stocks.
Strongbridge Biopharma has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Elevation Oncology has a net margin of 0.00% compared to Elevation Oncology's net margin of -115.67%. Strongbridge Biopharma's return on equity of -59.35% beat Elevation Oncology's return on equity.
In the previous week, Elevation Oncology's average media sentiment score of 0.00 equaled Strongbridge Biopharma'saverage media sentiment score.
Elevation Oncology has a consensus target price of $7.80, suggesting a potential upside of 117.88%. Given Strongbridge Biopharma's higher probable upside, analysts clearly believe Elevation Oncology is more favorable than Strongbridge Biopharma.
Summary
Strongbridge Biopharma and Elevation Oncology tied by winning 7 of the 14 factors compared between the two stocks.
Get Elevation Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELEV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevation Oncology Competitors List
Related Companies and Tools
